Vitamin & derivatives
01
Benfotiamine Fat-soluble vitamin B1 Lipid-soluble VB1
C19H23N4O6PS
Description
As a synthetic derivative of vitamin B1 (thiamine), benfotiamine significantly surpasses ordinary vitamin B1 in bioavailability, targeting and clinical efficacy through structural optimization and pharmacokinetic improvement. The specific advantages are as follows:
1. Structural innovation: lipid-soluble modification breaks through absorption limitations
Ordinary vitamin B1 (thiamine) is a water-soluble molecule that relies on intestinal sodium-dependent carriers (ThTr1/2) for active transport. It has a low absorption rate (<5%) and is easily saturated. High doses are easily excreted. Benfotiamine is converted into a lipid-soluble prodrug by introducing benzoyl and phosphate groups (structural formula C19H23N4O6PS), which can bypass carrier restrictions and directly penetrate intestinal mucosal cells through passive diffusion. The absorption efficiency is increased to more than 80%, and the bioavailability is 3-5 times that of ordinary B1 (J Clin Pharmacol, 2008).
2. Pharmacokinetic advantages: long-term effect and tissue targeting
Ordinary B1 has a short half-life in the blood (about 3.5 hours) and is easily cleared quickly by the kidneys. Benfotiamine is hydrolyzed into active thiamine by phosphatase in the body and further converted into thiamine pyrophosphate (TPP). Its lipid solubility makes it easier to accumulate in the phospholipid layer of the cell membrane, prolonging the duration of action (half-life> 6 hours). At the same time, its ability to penetrate the blood-brain barrier and nerve sheath is 8-10 times that of ordinary B1 (Neurochem Res, 2016), and it can effectively act on the central and peripheral nervous systems.
3. Metabolic regulation: Multi-target inhibition of glucotoxic damage
In a hyperglycemic environment, ordinary B1 is difficult to effectively inhibit abnormal glucose metabolism pathways due to poor tissue permeability. Benfotiamine shows unique advantages through the following mechanisms:
Blocking AGEs generation: inhibiting hexosamine and polyol pathways, reducing the accumulation of advanced glycation end products (AGEs), and alleviating axonal damage in diabetic neuropathy (Diabetes, 2010);
Anti-inflammatory and antioxidant: downregulating the activity of NF-κB and TXNIP/NLRP3 inflammasomes, reducing inflammatory factors such as IL-6 and TNF-α, while enhancing glutathione reductase activity and alleviating oxidative stress;
Mitochondrial protection: restoring the function of pyruvate dehydrogenase complex (PDH), improving the efficiency of tricarboxylic acid cycle, and reducing lactic acid accumulation.
4. Clinical efficacy: high-dose tolerance and deep repair
Ordinary B1 requires extremely high doses (≥300 mg/day) to treat diabetic neuropathy, but its efficacy is limited due to its absorption rate. Benfotiamine can stably increase tissue TPP concentration within the dose range of 150-600 mg/day. Clinical trials have shown that it can significantly improve nerve conduction velocity (+2.1 m/s vs placebo) and pain scores (VAS reduced by 40%), and there is no report of liver and kidney toxicity (Diabetes Care, 2005).
5. Stability and compatibility of preparations
Benfotiamine is significantly more stable than ordinary B1 in an acidic environment (pH 2.0-4.0) (degradation rate <5% vs >30%), and is compatible with a variety of multivitamins or drug preparations. Its lipid-soluble properties support the development of delivery systems such as nanoemulsions and liposomes, further improving the efficiency of targeted delivery.